RxDoctor Payments Data

Erika Kang

Psychiatric/Mental Health · Cumming, GANPI 1639568066

Payments from drug & device makers

$2,840in general payments, 2019–2025

Across 147 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$854
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$364
  • Johnson & Johnson$316
  • Otsuka America Pharmaceutical, Inc.$224
  • Axsome Therapeutics, Inc.$163
  • Lundbeck LLC$135
  • plus $784 from 14 others

What the payments were for

  • Food & beverage$2,79398%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,840 in reported general payments places this provider in the 85th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$11,285
Medicare patients
22
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Desvenlafaxine Succinate ErDesvenlafaxine Succinate26$1,522
Aripiprazole16$1,415
Olanzapine17$859
Clozapine14$606
Prazosin Hcl11$482
Bupropion XlBupropion Hcl24$468
Venlafaxine Hcl ErVenlafaxine Hcl12$385
Alprazolam61$313
Duloxetine Hcl11$268
Buspirone Hcl20$262
Lamotrigine18$231
Trazodone Hcl19$217
Mirtazapine11$158
Lorazepam20$90
Zolpidem Tartrate18$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$42$4711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →